BCN Biosciences is developing novel drugs in oncology as well as for the protection of normal tissues from radiation damage. They are committed to improving cancer treatment and diagnosis. The company manufactures innovative and effective medicines to treat cancer, one of the most serious diseases, with a team of experts in both drug discovery and oncology.

Holy Stone Healthcare Co., Ltd. engages in the research, development and manufacture of hyaluronic acid drugs and medical devices. It offers injectable devices for osteoarthritis and soft tissue injuries. The company also provides hyaluronic acid and mesalamine capsules for inflammatory bowel diseases. Holy Stone Healthcare was founded on January 18, 2001 and is headquartered in Taipei, Taiwan.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Manufactures and supplies ethical and proprietary medicines, veterinary products, laboratory and educational scientific equipment, clinical diagnostic supplies and garden products

Indena is the world’s leading company in the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and personal care industries.Indena, a privately owned Italian company, has around 800 employees (10% of them dedicated to full-time research) and has cultivation, manufacturing, and sales in more than 70 countries throughout the world.

MicroPharm is a fully integrated developer and manufacturer of polyclonal therapeutics, targeting infectious disease and acute toxic events. MicroPharm's core expertise lies in the raising of antisera containing high levels of specific antibodies directed against toxic molecules or viral targets and the subsequent purification and modification of such antibodies to produce a range of immunotherapeutic products for clinical use. All are designed to treat acute, life-threatening emergencies, have been developed at the request of the medical profession and are required urgently either because no alternative exists or because any alternative is ineffective and/or unsafe. MicroPharm also provides a contract development, manufacturing and filling service to third parties.

Ferring BV offers pharmaceutical products. It offers medicines in Gynaecology, Gastroenterology, Endocrinology and Urology. The company was founded in 1984 and is headquartered in Hoofddorp, Netherlands.

Bio.lo.ga Srl is a private company headquartered in Conegliano, Italy. The firm manufactures pharmaceutical products.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Genetics Institute is a U.S. based biotechnology research and development company. The company developed drugs such as Neumega and Recombinate used in the prevention of severe reductions in the number of blood clotting cells. The company was founded in 1980 by Thomas Maniatis and Mark Ptashne, and started off by operating out of Ptashne’s home. Genetics Institute was acquired by Wyeth in 1992 and operates as part of Wyeth’s research division.

Salient is a Texas-based company formed in 2007 to explore the pharmaceutical application of its proprietary composition of a rare, all-natural mineral. This composition has been proven to adsorb a range of toxins and inflammatory proteins commonly associated with diarrhea. Salient’s compound, CASAD™, is envisioned to be a “platform” product effective across a spectrum of conditions from Cancer Therapy-Induced Diarrhea to infectious disease and chronic GI conditions. It also has the potential to be used as a rescue agent for other drugs with toxic side effects.

Hongyun Pharmaceutical (Kunming) Co., Ltd., established on 1994-09-05, Business scope includes pharmaceuticals,Pre-packaged food,Production and sales of bulk food;Medical equipment and equipment,Manufacturing and sales of cosmetics;Agricultural and sideline products,Sales of daily necessities;Business agency service;Goods and technology import and export business(Except for goods and technologies that the state restricts the company to operate or prohibits the import and export of goods and technologies);Research and development of biotechnology,technical consulting;Planting of Chinese herbal medicines(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Yunnan Kunchuan Electronic Equipment Co., Ltd., established on 1998-04-24, Business scope includes logistics system,Industrial Automatic Control System,Electronic instrumentation,Electronic Information System Integration,Electrical and Electronic Equipment,tobacco equipment,Belt conveyor,Weighing equipment,Green facilities,Chinese medicine extraction equipment,Granule packaging equipment,electric motor,transformer,Rectifiers and Inductors,plastic products,rubber products,wooden products,Building Automation Engineering,electric,Design and manufacture of products such as pipelines and equipment,Sales,Installation and Technical Services,information,consult;Electronic and electrical testing and testing technology services;Value-added Telecom Services,Agricultural and sideline products,Prepackaged food sales,Community life service and information consultation, etc.;Operating various"Tertiary industry"business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shijiazhuang Ping An Hospital Co., Ltd., established on 2006-11-09, Business scope includes medical services(The operating permit);car park service;Realtor;food sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Antibe Therapeutics develops novel anti-inflammatory drugs that are improved versions of existing drugs. They focus on diseases characterized by inflammation, pain, and/or vascular dysfunction. Their drug design approach is to create new drugs by improving existing, proven drugs. The company's technology platform enables us to chemically link an existing drug to a hydrogen sulfide-releasing moeity. Hydrogen sulfide (H2S) is one of several so-called gaseous mediators. Gaseous mediators are naturally occurring substances found in the human body. Acting as neuromodulators, immunomodulators, and vasodilators, gaseous mediators such as H2S regulate fundamental cellular processes. Antibe believes that H2S has tremendous therapeutic potential. Antibe’s R&D is guided by a leading team of pharmaceutical researchers and advisors. The team includes a Nobel Prize winner, highly successful entrepreneurs, and senior scientists affiliated with major research institutions worldwide.

Shanxi Zhendong Pharmaceutical Co., Ltd. engages in the research and development, manufacture and distribution of Chinese traditional medicines and western medicines. Its products include Yanshu injection, Norfloxacin, Shuxuening injection, Guanxinning injection, Amoxicillin Sodium for injection, Cefathiamidine for injection and Riboflavin Sodium Phosphate for injection. The company was founded on November 22, 1993 and is headquartered in Changzhi, China.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Techfields, Inc. is an American private company located in Princeton, NJ, that operates as clinical stage pharmaceutical company that develops medicines for inflammatory diseases. It was founded by Chongxi Yu and Lina Xu. Chongxi Yu is currently the CEO of the firm.